Acoramidis treatment attenuates the rise in N-terminal pro-B-type natriuretic peptide from baseline to month 30 compared with placebo across participant subgroups in ATTRibute-CM

European Journal of Heart Failure 2026

View at publisher
Authors: P Soman, N Sarswat, A Masri, K Bhatt, M Fontana, P Garcia-Pavia, O Akinboboye, R K Cheng, C Chen, J F Tamby, J C Fox, J D Gillmore
+3 more D P Judge, J L Januzzi Jr, M G Khouri
DOI: 10.1093/ejhf/xuag193.1133
Cited by: 1

Abstract

Abstract Background Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative, restrictive, life threatening, progressive disease caused by the destabilization of transthyretin (TTR) tetramers. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a biomarker of disease progression, and progressive rises in its levels are associated with increased mortality. Acoramidis, an oral, near-complete (≥90%) TTR stabilizer, is approved in the US, Europe, Japan, and UK for the treatment of ATTR-CM. In the 30-month, phase 3 ATTRibute-CM study, acoramidis treatment significantly attenuated the rise in NT-proBNP levels compared with placebo (p

Fields of Study & Subjects

Amyloidosis: Diagnosis Treatment Outcomes Coagulation Bradykinin Polyphosphates and Angioedema Parathyroid Disorders and Treatments

Publication details

Journal / source
European Journal of Heart Failure
Publisher
Oxford University Press (OUP)
Volume
28
Issue
Supplement_2
Publication date
1 June 2026
Language
EN